High uptake of RSVpreF vaccine and nirsevimab was observed, with 64% of pregnant individuals and 70% of infants receiving ...

The new research, published Monday (Dec. 9) in the journal JAMA Pediatrics, focused on nirsevimab (Beyfortus), a drug approved in 2023. The medicine, which is given as an injection, uses lab-made ...

The medication – nirsevimab – is given via injection to infants under 8 months old. Unlike a vaccine, the immunization ...

This sick season, there is expanded access to a new immunization that can help protect babies from getting sick.

A study today in JAMA Network Open from the University of California, San Francisco (UCSF), shows a high uptake of respiratory syncytial virus (RSV) vaccine and the RSV-preventing monoclonal antibody ...

When existing systems do not accommodate access to health care innovation, we must change those systems. Fulfilling nirsevimab’s promise will require overcoming entrenched hospital payment norms.

A cohort study found that nearly three fourths of infants received respiratory syncytial virus protection with either nirsevimab or through exposure to maternal RSVpreF in the 2023-2024 season.

It is the first approval for Beyfortus (nirsevimab) by any regulatory authority. AZ's Synagis (palivizumab) is currently the only approved drug in Europe to provide passive prophylaxis against RSV ...

Sanofi and AstraZeneca are closing in on EU approval of nirsevimab, their long-acting antibody for the protection of newborns and infants from respiratory syncytial virus (RSV) infections.

Inhalon’s inhaled antibody therapy aims to address this need, the release said. Its RSV candidate is part of a more broad effort to develop therapies that deliver therapeutic antibodies directly to ...

The one-off therapy, nirsevimab, is designed to protect again illness from respiratory syncytial virus (RSV) which can be deadly for infants. RSV is one of a number of viruses that surge in winter ...

USA: Researchers have found in a new study that a respiratory syncytial virus (RSV) prevention strategy combining prenatal ...